KLRK1 and melanoma: They express NK group two member D ligands (NKG2DLs) and interleukin‐15 receptor alpha (IL‐15 Rα), promoting proliferation and IFN‐γ secretion by NK cells.[197, 198] DEXs also provide ligands such as BAT3/BAG6 for NCR3 and MICA/MICB for NKG2D, directly triggering NK activation.[197, 199] In murine melanoma models, these molecules supported IL‐15 Rα and NKG2D‐dependent NK cell proliferation and IFN‐γ release, leading to antimetastatic effects.